{
  "id": 10931460,
  "title": "Immunome receives FDA clearance for IM-1340 solid tumor trial",
  "url": "https://urgent.news/2026/09/30/immunome-receives-fda-clearance-for-im-1340-solid-tumor-trial",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-30T11:52:29.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/immunome-receives-fda-clearance-for-im1340-solid-tumor-trial-93CH-4924949"
  },
  "original_language": "en",
  "account": "Immunome Inc., a clinical-stage targeted oncology company based in Bellingham, Washington, has received approval from the U.S. Food and Drug Administration for its investigational drug IM-1340. This antibody-drug conjugate aims to treat advanced solid tumors, which include neuroendocrine tumors, lung cancer, and colorectal cancer. IM-1340 utilizes HC74, a topoisomerase I inhibitor payload developed by Immunome.\n\nThe company plans to commence a Phase 1 first-in-human study of IM-1340 in patients with advanced solid tumors in the fourth quarter of 2026. This trial will be an open-label, multicenter dose-escalation and expansion study, with the aim of assessing the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of the investigational therapy.\n\nClay Siegall, Immunome's President and Chief Executive Officer, expressed enthusiasm about this milestone, stating that the IND clearance for IM-1340 demonstrates the company's ability to rapidly advance novel programs into the clinic. Immunome's other investigational programs include varegacestat, an investigational gamma secretase inhibitor, IM-1021, a ROR1 ADC, IM-1617, a solid tumor ADC, and IM-3050, a FAP-targeted radiotherapy.",
  "summary": null,
  "key_points": [
    "FDA clears IM-1340 for solid tumor trial",
    "Phase 1 study to start Q4 2026",
    "Targets neuroendocrine, lung, colorectal cancers"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}